VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Files An 8-K Other EventsItem 8.01 Other Events.
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Files An 8-K Other Events
On April 27, 2017, VistaGen Therapeutics, Inc. (the “Company”) announced the peer-reviewed publication of nonclinical studies of the effects of AV-101(4-Cl-KYN), the Company’s central nervous system (CNS) prodrug candidate, in four well-established nonclinical models of pain. The publication, titled: “Characterization of the effects of L-4-chlorokynurenine on nociception in rodents,” by lead author,Tony L. Yaksh, Ph.D., Professor in Anesthesiology at the University of California, San Diego (UCSD), and co-authors,Robert Schwarcz, Ph.D., Professor of Psychiatry and Pharmacology, University of Maryland School of Medicine, andH. Ralph Snodgrass, Ph.D.,President and Chief Scientific Officer of VistaGen Therapeutics, was recently published in The Journal of Pain (DOI: 10.1016/j.jpain.2017.03.014). A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1, and is incorporated herein by reference.
Item 9.01 Exhibits.
See Exhibit Index.
About VistaGen Therapeutics, Inc. (NASDAQ:VTGN)
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressants approved by the United States Food and Drug Administration (FDA). In addition to AV-101, the Company has developed a human pluripotent stem cell (hPSC) technology platform, which includes its in-vitro bioassay system, CardioSafe 3D, to predict potential heart toxicity of new chemical entities (NCEs) long before testing in animal and human studies. The Company is focused on regenerative medicine (RM) applications using blood, cartilage, heart and/or liver cells derived from hPSCs. VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Recent Trading Information
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) closed its last trading session up +0.01 at 1.98 with 2,964 shares trading hands.
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressants approved by the United States Food and Drug Administration (FDA). In addition to AV-101, the Company has developed a human pluripotent stem cell (hPSC) technology platform, which includes its in-vitro bioassay system, CardioSafe 3D, to predict potential heart toxicity of new chemical entities (NCEs) long before testing in animal and human studies. The Company is focused on regenerative medicine (RM) applications using blood, cartilage, heart and/or liver cells derived from hPSCs. VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Recent Trading Information
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) closed its last trading session up +0.01 at 1.98 with 2,964 shares trading hands.
